BASi is a drug development firm providing contract research services and unique products for the pharmaceutical, biotechnology and medical device industries.
The determination of the in vivo concentration of acetylcholine(ACh) is important in the study of cognitive function and dysfunction. In these circumstances only ACh concentration(ACh peak) is of interest; however, a large choline concentration(Ch peak) may interfere with the ACh peak. The Ch peak can be excluded from the chromatogram by placing a choline oxidase/catalase IMER (MF-8907) prior to the analytical column. The choline oxidase oxidizes the choline to betaine and H2O2 and the catalase catalyzes the decomposition of H2O2 to H2O and O2 prior to the analytical column.
In order to increase the basal extracellular ACh concentration to readily detectable levels, most of these studies have employed acetylcholinesterase inhibitors. This artificially increased concentration of ACh may significantly influence the cholinergic system, especially if the goal of the study is the development of a drug or condition that increases the availability of brain ACh. The introduction of the present Precolumn-IMER has allowed for the quantitation of ACh in dialysates without the use of acetylcholine inhibitors. See www.currentseparations.com Vol. 19:2, (2000), Acetylcholinesterase Inhibitors Are Neither Necessary nor Desirable for Microdialysis Studies of Brain Acetylcholine.
For Research Purposes Only. Not For Diagnostic Use. |
